Literature DB >> 16186218

Ectromelia virus: the causative agent of mousepox.

David J Esteban1, R Mark L Buller2.   

Abstract

Ectromelia virus (ECTV) is an orthopoxvirus whose natural host is the mouse; it is related closely to Variola virus, the causative agent of smallpox, and Monkeypox virus, the cause of an emerging zoonosis. The recent sequencing of its genome, along with an effective animal model, makes ECTV an attractive model for the study of poxvirus pathogenesis, antiviral and vaccine testing and viral immune and inflammatory responses. This review discusses the pathogenesis of mousepox, modulation of the immune response by the virus and the cytokine and cellular components of the skin and systemic immune system that are critical to recovery from infection.

Entities:  

Mesh:

Year:  2005        PMID: 16186218     DOI: 10.1099/vir.0.81090-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  92 in total

1.  Perforin-dependent CD4+ T-cell cytotoxicity contributes to control a murine poxvirus infection.

Authors:  Min Fang; Nicholas A Siciliano; Adam R Hersperger; Felicia Roscoe; Angela Hu; Xueying Ma; Ahamed R Shamsedeen; Laurence C Eisenlohr; Luis J Sigal
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-04       Impact factor: 11.205

2.  N1L is an ectromelia virus virulence factor and essential for in vivo spread upon respiratory infection.

Authors:  Meike S Gratz; Yasemin Suezer; Melanie Kremer; Asisa Volz; Monir Majzoub; Kay-Martin Hanschmann; Ulrich Kalinke; Astrid Schwantes; Gerd Sutter
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

3.  The Inhibitory Receptor NKG2A Sustains Virus-Specific CD8⁺ T Cells in Response to a Lethal Poxvirus Infection.

Authors:  Aaron S Rapaport; Jill Schriewer; Susan Gilfillan; Ed Hembrador; Ryan Crump; Beatrice F Plougastel; Yaming Wang; Gaelle Le Friec; Jian Gao; Marina Cella; Hanspeter Pircher; Wayne M Yokoyama; R Mark L Buller; Marco Colonna
Journal:  Immunity       Date:  2015-12-08       Impact factor: 31.745

4.  Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function.

Authors:  Vijay Panchanathan; Geeta Chaudhri; Gunasegaran Karupiah
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

5.  Poxvirus-encoded gamma interferon binding protein dampens the host immune response to infection.

Authors:  Isaac G Sakala; Geeta Chaudhri; R Mark Buller; Anthony A Nuara; Hongdong Bai; Nanhai Chen; Gunasegaran Karupiah
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

6.  Comparable polyfunctionality of ectromelia virus- and vaccinia virus-specific murine T cells despite markedly different in vivo replication and pathogenicity.

Authors:  Adam R Hersperger; Nicholas A Siciliano; Laurence C Eisenlohr
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

7.  Loss of cytoskeletal transport during egress critically attenuates ectromelia virus infection in vivo.

Authors:  Helena Lynn; Jacquelyn Horsington; Lee Kuan Ter; Shuyi Han; Yee Lian Chew; Russell J Diefenbach; Michael Way; Geeta Chaudhri; Gunasegaran Karupiah; Timothy P Newsome
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

Review 8.  Initiation of primary anti-vaccinia virus immunity in vivo.

Authors:  Matthew A Fischer; Christopher C Norbury
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

9.  Characterization of ectromelia virus deficient in EVM036, the homolog of vaccinia virus F13L, and its application for rapid generation of recombinant viruses.

Authors:  Felicia Roscoe; Ren-Huan Xu; Luis J Sigal
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

10.  Poor Antigen Processing of Poxvirus Particles Limits CD4+ T Cell Recognition and Impacts Immunogenicity of the Inactivated Vaccine.

Authors:  Katherine S Forsyth; Brian DeHaven; Mark Mendonca; Sinu Paul; Alessandro Sette; Laurence C Eisenlohr
Journal:  J Immunol       Date:  2019-01-30       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.